Long 2009.

Methods	Trial design: randomised trial
Participants	Participants: 70 women with moderate or severe endometriosis Mean age:  in GnRHa group was 31±7 years and in the add‐back group was 32±7 years in those who completed the study Inclusion criteria: not stated  Exclusion criteria: not stated  Setting: China Timing: not stated
Interventions	GnRHa Zoladex 3.6 mg every 28 days (x3) (n = 35)  versus  Zoladex 3.6 mg every 28 days (x3)+ add‐back‐ oestradiol valerate 0.5 mg + dydrogesterone 5 mg daily (n = 35)
Outcomes	Relief of overall pain Quality of life Bone mineral density Patients satisfaction
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated  Funding: not stated   This abstract did not contain enough information to make a proper decision about in‐/exclusion.